News

Video

Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC

Author(s):

Shirish Gadgeel, MD

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Metastatic NSCLC | Image Credit: © catalin – stock.adobe.com
April 24th 2025

Optune Lua Granted CE Mark Approval in EU for Metastatic NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Fawzi F Abu Rous, MD
April 23rd 2025

Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Fawzi F Abu Rous, MD, thoracic medical oncologist, Henry Ford Health
April 21st 2025

Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung

Isabel Preeshagul, DO, MBS
April 20th 2025

Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC